The University of Western Australia
Asst/Prof Danielle Meyrick
Assistant Professor
Contact details
| Address | Pharmacy Program The University of Western Australia (M315) 35 Stirling Highway CRAWLEY WA 6009 Australia |
|---|---|
| Phone | 6488 3199 |
| Fax | 6488 1025 |
| danielle.meyrick@uwa.edu.au |
Location
Room 2.01C, Old Biochemistry Building, Crawley campus
Biography
Key Research Interests
Radiopharmaceuticals
Metal ions in biological systems
Isolation and characterization of bioactive compounds from natural sources
Bioinorganic chemistry and biomineralisation
Drug stability
Dr Danielle Meyrick completed her Bachelor of Science with a double major in chemistry and extractive metallurgy- mineral science at Murdoch University, where she went on to do a PhD in physical chemistry. She was then employed by the Department of Nuclear Medicine at Fremantle Hospital as Senior Scientist and Radiochemist and lectured at Murdoch University before moving to UWA. Dr Meyrick is also the Director of the Radiopharmaceutical Chemistry for the Australian Institute of Radiochemical Engineering and academic convener of the Australian Institute of Nuclear Science and Engineering Winter School. She has been nominated for a position on the Radiological Council of Western Australia.
Radiopharmaceuticals
Metal ions in biological systems
Isolation and characterization of bioactive compounds from natural sources
Bioinorganic chemistry and biomineralisation
Drug stability
Dr Danielle Meyrick completed her Bachelor of Science with a double major in chemistry and extractive metallurgy- mineral science at Murdoch University, where she went on to do a PhD in physical chemistry. She was then employed by the Department of Nuclear Medicine at Fremantle Hospital as Senior Scientist and Radiochemist and lectured at Murdoch University before moving to UWA. Dr Meyrick is also the Director of the Radiopharmaceutical Chemistry for the Australian Institute of Radiochemical Engineering and academic convener of the Australian Institute of Nuclear Science and Engineering Winter School. She has been nominated for a position on the Radiological Council of Western Australia.
Key research
- Dr Meyrick's research focuses primarily on the development and application of novel radiopharmaceuticals for imaging and therapy in nuclear medicine. The laboratory also focuses on the elucidation of the in-vivo physical chemistry of therapeutic radiopharmaceuticals, with the aim of improving existing therapeutic protocols and outcomes.
- The exploitation of molecular targets associated with disease processes or tumour growth allows the targeted delivery of radioactivity directly to disease sites. The targeting entities, which are bound to a radioisotope, may incorporate biomolecules, such as peptides or antibodies, complexing agents or micro- or nanosystems. This very specific delivery of radioactivity allows imaging and assessment of organ function and, in the case of cancer therapy, effective tumour ablation and treatment of disease with few associated side effects to the patient.
- Radioisotopes for inclusion in radiopharmaceuticals of particular interest to this group are Re-188, Cu-64 and Ga-68. The selection of radioisotope depends upon its availability, half-life, chemistry and intended application; isotopes used for positron emission tomography (PET) imaging have different nuclear properties than those used for cancer therapy. There is enormous potential for the development of radiopharmaceuticals in cancer management, and it is an area attracting increasing interest worldwide. Projects in this laboratory are undertaken in association with the Department of Nuclear Medicine at Fremantle Hospital and, pending institutional ethics committee approval, many reach the clinical pilot trial stage.
- The laboratory also focuses on elucidating the in vivo physical/solution chemistry of radiopharmaceuticals and other drugs incorporating metals. There is a broad interest in bioinorganic chemistry, including biomineralisation, and the thermodynamics of metal ions in biological systems. Additionally, Dr Meyrick is developing research projects in natural products chemistry, isolating and characterising bioactive compounds from marine species such as sponges, with the aim being to develop efficacious radiopharmaceuticals. The group also has interests in assessing ex-vivo drug stability and interactions.
Major research interests
- Biominerals, bioinorganic chemistry
- Radiopharmaceutical
- Solution chemistry
Qualifications
BSc PhD Murd.
Publications
Recent Publications
Moorin, R.E., Meyrick, D.P., Rose, A. Pre-clinical Evaluation of 2,3-dimercaptosuccinic acid (DMSA) as a Radiation Nephrotxicity Protective Agent During Radiopeptide Therapy of Neuroendocrine Malignancy, Nuclear Medicine Communications, 28(4): pp 261-266 (2007)
Chirila, T.V., Morrison, D.A., Gridvena, Z., Meyrick, D., Hicks, C.R., Webb, J.M. Effect of multi-purpose solutions for contact lens care on the in vitro drug-induced spoliation of poly (2-hydroxyethyl methacrylate) in simulated aqueous humour, Contact Lens and Anterior Eye, 28: pp 21-28 (2005)
Meyrick, D., Webb, J., Cole, C. Iron and Iron Proteins in the Genetic Disease, Hereditary Spherocytosis, Inorganica Chimica Acta, 339: pp 481-487 (2002)
Cole, C., Meyrick, D., Webb, J. Spleen Tissue Iron in Hereditary Spherocytosis, Blood, 96 (11) (2000)
Technical Reports
Königsberger, E., Königsberger, Meyrick, D.P. L.-C., Molinari, C., and May, P. Concentrated Acidic Solutions of High Silica Bauxite Ores. Report to CSIRO Minerals. (2008)
Recent Conference Papers
Morandeau, L., de Grado, T., McKinney, C.J., Chan, S.Y., Meyrick, D.P., Jones, C.G., Price, R.I. Automated Synthesis of [18F] Fluoromethylcholine (FCH). Sixteenth International Symposium on Radiopharmaceutical Chemistry, Iowa City, USA, June, (2005)
Meyrick, D., Rose, A., Morandeau, L., Webb, J., Turner, J.H. Biodistribution of Two New Samarium-153 Bisphosphonate Complexes. PBA 2004, Fifteenth International Symposium on Pharmaceutical and Biomedical Analysis, Florence, Italy, May (2004)
Meyrick, D., Webb, J., Carr, S., Analysis and Adsorption of Samarium Ethylenediamine Tetramethylene Phosphonic Acid to Hydroxyapatite. PBA 2004, Fifteenth International Symposium on Pharmaceutical and Biomedical Analysis, Florence, Italy, May (2004)
Meyrick, D., Webb, J., Carr, S. Adsorption of Samarium Ethylenediamine Tetramethylene Phosphonic Acid to Hydroxyapatite: An In Vitro Model for the Uptake of the Radiopharmaceutical in Bone Tissue. Fifteenth International Symposium on Radiopharmaceutical Chemistry, Sydney, Australia, August (2003) Abstract published in Journal of Labeled Compounds and Radiopharmaceuticals (2003) 46 (1).
Meyrick, D., Webb, J., Cole, C. Tissue Iron Deposits in Hereditary Spherocytosis. World Chemistry Congress, Brisbane, July (2001)
Moorin, R.E., Meyrick, D.P., Rose, A. Pre-clinical Evaluation of 2,3-dimercaptosuccinic acid (DMSA) as a Radiation Nephrotxicity Protective Agent During Radiopeptide Therapy of Neuroendocrine Malignancy, Nuclear Medicine Communications, 28(4): pp 261-266 (2007)
Chirila, T.V., Morrison, D.A., Gridvena, Z., Meyrick, D., Hicks, C.R., Webb, J.M. Effect of multi-purpose solutions for contact lens care on the in vitro drug-induced spoliation of poly (2-hydroxyethyl methacrylate) in simulated aqueous humour, Contact Lens and Anterior Eye, 28: pp 21-28 (2005)
Meyrick, D., Webb, J., Cole, C. Iron and Iron Proteins in the Genetic Disease, Hereditary Spherocytosis, Inorganica Chimica Acta, 339: pp 481-487 (2002)
Cole, C., Meyrick, D., Webb, J. Spleen Tissue Iron in Hereditary Spherocytosis, Blood, 96 (11) (2000)
Technical Reports
Königsberger, E., Königsberger, Meyrick, D.P. L.-C., Molinari, C., and May, P. Concentrated Acidic Solutions of High Silica Bauxite Ores. Report to CSIRO Minerals. (2008)
Recent Conference Papers
Morandeau, L., de Grado, T., McKinney, C.J., Chan, S.Y., Meyrick, D.P., Jones, C.G., Price, R.I. Automated Synthesis of [18F] Fluoromethylcholine (FCH). Sixteenth International Symposium on Radiopharmaceutical Chemistry, Iowa City, USA, June, (2005)
Meyrick, D., Rose, A., Morandeau, L., Webb, J., Turner, J.H. Biodistribution of Two New Samarium-153 Bisphosphonate Complexes. PBA 2004, Fifteenth International Symposium on Pharmaceutical and Biomedical Analysis, Florence, Italy, May (2004)
Meyrick, D., Webb, J., Carr, S., Analysis and Adsorption of Samarium Ethylenediamine Tetramethylene Phosphonic Acid to Hydroxyapatite. PBA 2004, Fifteenth International Symposium on Pharmaceutical and Biomedical Analysis, Florence, Italy, May (2004)
Meyrick, D., Webb, J., Carr, S. Adsorption of Samarium Ethylenediamine Tetramethylene Phosphonic Acid to Hydroxyapatite: An In Vitro Model for the Uptake of the Radiopharmaceutical in Bone Tissue. Fifteenth International Symposium on Radiopharmaceutical Chemistry, Sydney, Australia, August (2003) Abstract published in Journal of Labeled Compounds and Radiopharmaceuticals (2003) 46 (1).
Meyrick, D., Webb, J., Cole, C. Tissue Iron Deposits in Hereditary Spherocytosis. World Chemistry Congress, Brisbane, July (2001)
Funding received
Australian Institute of Nuclear Science and Engineering
Australian and New Zealand Society of Nuclear Medicine
University of Western Australia
Australian and New Zealand Society of Nuclear Medicine
University of Western Australia
Memberships
Australian and New Zealand Society of Nuclear Medicine
Women in Science Enquiry Network
Women in Science Enquiry Network
Teaching
Students
Ms. Jessie Monoidis (Hons): Isolation and characterization of bioactive compounds from marine sponges.
Ms. Nurshahidah Ali (PhD)- Reducing the renal radiation burden during peptide receptor radiation therapy for neuroendocrine tumours.
Potential Research Projects
Example research projects available include:
1. Direct labeling of peptides and antibodies with Re-188 for treatment of malignancy.
2. Development of Cu-64/67 labeled peptides for combined PET imaging and therapy of neuroendocrine tumours.
3. Assessing the bactericidal and bacteriostatic properties of positron emitting radioisotopes.
4. Investigation and modeling of the thermodynamic behaviour of zirconium in biological systems.
5. Evaluation of the stability of intravenous paracetamol formulations.
There are other projects available in the areas of radiometals, bioinorganic chemistry and metals in medicine, and all discussions are welcomed.
Projects for Prospective Chemistry Honours Students
Students with an interest in the applications of chemistry to biological systems (including those discussed above) should note that there are joint Pharmacy/Chemistry projects available. These are to be completed under the joint supervision of Chemistry and Pharmacy.
Lecturing
CHEM8612 Medicinal Chemistry I
CHEM8613 Medicinal Chemistry II
CHEM3307 Metals in Biological Chemistry
PHCY8611 Pharmaceutical Technology
Ms. Jessie Monoidis (Hons): Isolation and characterization of bioactive compounds from marine sponges.
Ms. Nurshahidah Ali (PhD)- Reducing the renal radiation burden during peptide receptor radiation therapy for neuroendocrine tumours.
Potential Research Projects
Example research projects available include:
1. Direct labeling of peptides and antibodies with Re-188 for treatment of malignancy.
2. Development of Cu-64/67 labeled peptides for combined PET imaging and therapy of neuroendocrine tumours.
3. Assessing the bactericidal and bacteriostatic properties of positron emitting radioisotopes.
4. Investigation and modeling of the thermodynamic behaviour of zirconium in biological systems.
5. Evaluation of the stability of intravenous paracetamol formulations.
There are other projects available in the areas of radiometals, bioinorganic chemistry and metals in medicine, and all discussions are welcomed.
Projects for Prospective Chemistry Honours Students
Students with an interest in the applications of chemistry to biological systems (including those discussed above) should note that there are joint Pharmacy/Chemistry projects available. These are to be completed under the joint supervision of Chemistry and Pharmacy.
Lecturing
CHEM8612 Medicinal Chemistry I
CHEM8613 Medicinal Chemistry II
CHEM3307 Metals in Biological Chemistry
PHCY8611 Pharmaceutical Technology
Current projects
Collaborators
Department of Nuclear Medicine, Fremantle Hospital, Western Australia
School of Chemical and Mathematical Sciences, Murdoch University, Western Australia
University of Ferrara, Ferrara, Italy
Affiliations
Australian Institute of Nuclear Science and Engineering
Australian Institute of Radiochemical Engineering
Department of Nuclear Medicine, Fremantle Hospital, Western Australia
School of Chemical and Mathematical Sciences, Murdoch University, Western Australia
University of Ferrara, Ferrara, Italy
Affiliations
Australian Institute of Nuclear Science and Engineering
Australian Institute of Radiochemical Engineering
Research profile
